Biotech Companies Make Merger Deals | November 2, 2009 Issue - Vol. 87 Issue 44 | Chemical & Engineering News
Volume 87 Issue 44 | p. 15 | Concentrates
Issue Date: November 2, 2009

Biotech Companies Make Merger Deals

Department: Business
Keywords: biotech, merger

Ligand Pharmaceuticals will acquire Metabasis Therapeutics by initially paying about $1.8 million to Metabasis stockholders and making future cash payments if it sells or finds partners for any Metabasis drug development programs. Ligand has agreed to spend at least $8 million in new R&D funding on the Metabasis programs within 42 months of closing the deal. In a more traditional merger, BioMarin Pharmaceutical has paid $15 million to acquire Huxley Pharmaceuticals and its amifampridine phosphate drug for treating Lambert Eaton Myasthenic Syndrome, a rare autoimmune disease. BioMarin will make up to $43.5 million in other payments if the drug hits certain milestones.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment